Rebamipide nanosuspension was created through the utilization of the solvent diffusion method, and their properties were examined across several parameters. These assessments encompassed the determination of particle size and structure, zeta potential, encapsulation efficiency, in-vitro drug release behavior, and ex-vivo therapeutic effectiveness. The experiment revealed that altering the drug-to-polymer ratio had an impact on the particle size. The particulate formulation demonstrated a sustained drug release in-vitro profile, following the Korsmeyer-Peppas kinetic model, indicating controlled drug release over time. The drug release from the nanosuspension occurs through a combination of processes involving both dissolution and diffusion. This observation is supported by the experimental results obtained. The ideal formulation displayed a particle size of 196.0 nm and possessed a zeta potential of +32.5 mv. The particles were spherical in shape, and their uniformity was indicated by a low polydispersity index of 0.188. Differential Scanning Calorimetry and XRD studies showed a reduction in the crystalline nature of the drug. During ex-vivo transcorneal studies using excised goat corneas, it was observed that the drug's transcorneal permeation was higher when compared to the suspension of the drug. This increased permeation was achieved without causing any damage to the cornea. Additionally, stability studies indicated that the formulation remained stable under the specified conditions, further highlighting its potential as a drug delivery system